These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 16521031)

  • 1. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.
    Walther S; Mahlberg R; Eichmann U; Kunz D
    Psychopharmacology (Berl); 2006 May; 185(4):524-8. PubMed ID: 16521031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms.
    Woodward MR; Harper DG; Stolyar A; Forester BP; Ellison JM
    Am J Geriatr Psychiatry; 2014 Apr; 22(4):415-9. PubMed ID: 23597932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actigraphy in agitated patients with dementia. Monitoring treatment outcomes.
    Mahlberg R; Walther S
    Z Gerontol Geriatr; 2007 Jun; 40(3):178-84. PubMed ID: 17565435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia.
    Sommer OH; Aga O; Cvancarova M; Olsen IC; Selbaek G; Engedal K
    Dement Geriatr Cogn Disord; 2009; 27(2):155-63. PubMed ID: 19182483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preliminary pilot study of cyproterone acetate for the treatment of aggressive behavior associated with severe dementia].
    Caparros-Lefebvre D; Dewailly D
    Rev Neurol (Paris); 2005 Nov; 161(11):1071-8. PubMed ID: 16288172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial.
    van den Elsen GA; Ahmed AI; Verkes RJ; Kramers C; Feuth T; Rosenberg PB; van der Marck MA; Olde Rikkert MG
    Neurology; 2015 Jun; 84(23):2338-46. PubMed ID: 25972490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bright light treatment of behavioral and sleep disturbances in patients with Alzheimer's disease.
    Satlin A; Volicer L; Ross V; Herz L; Campbell S
    Am J Psychiatry; 1992 Aug; 149(8):1028-32. PubMed ID: 1353313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study.
    Mahlberg R; Walther S; Eichmann U; Tracik F; Kunz D
    Arch Gerontol Geriatr; 2007; 45(1):19-26. PubMed ID: 16963137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community.
    Matsumoto N; Ikeda M; Fukuhara R; Shinagawa S; Ishikawa T; Mori T; Toyota Y; Matsumoto T; Adachi H; Hirono N; Tanabe H
    Dement Geriatr Cogn Disord; 2007; 23(4):219-24. PubMed ID: 17299264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly.
    Laks J; Engelhardt E; Marinho V; Rozenthal M; Souza FC; Bacaltchuk J; Stoppe A; Ferreira RC; Bottino C; Scalco M
    Arq Neuropsiquiatr; 2001 Dec; 59(4):859-64. PubMed ID: 11733828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral problems in dementia. Strategies for pharmacologic and nonpharmacologic management.
    Smith AG
    Postgrad Med; 2004 Jun; 115(6):47-52, 55-6. PubMed ID: 15216573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amisulpride in the treatment of behavioural disturbances among patients with moderate to severe Alzheimer's disease.
    Mauri M; Mancioli A; Rebecchi V; Corbetta S; Colombo C; Bono G
    Acta Neurol Scand; 2006 Aug; 114(2):97-101. PubMed ID: 16867031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of melatonin in selected populations of sleep-disturbed patients.
    Brusco LI; Fainstein I; Márquez M; Cardinali DP
    Biol Signals Recept; 1999; 8(1-2):126-31. PubMed ID: 10085474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tailored lighting intervention improves measures of sleep, depression, and agitation in persons with Alzheimer's disease and related dementia living in long-term care facilities.
    Figueiro MG; Plitnick BA; Lok A; Jones GE; Higgins P; Hornick TR; Rea MS
    Clin Interv Aging; 2014; 9():1527-37. PubMed ID: 25246779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study.
    Freund-Levi Y; Bloniecki V; Auestad B; Tysen Bäckström AC; Lärksäter M; Aarsland D
    Dement Geriatr Cogn Disord; 2014; 38(3-4):234-44. PubMed ID: 24969380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
    Forester B; Vanelli M; Hyde J; Perez R; Ahokpossi C; Sribney W; Adkison L
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):209-17. PubMed ID: 17996660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sleep disturbance, nocturnal agitation behaviors, and medical comorbidity in older adults with dementia: relationship to reported caregiver burden.
    Kim SS; Oh KM; Richards K
    Res Gerontol Nurs; 2014; 7(5):206-14. PubMed ID: 24877599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction.
    Senanarong V; Cummings JL; Fairbanks L; Mega M; Masterman DM; O'Connor SM; Strickland TL
    Dement Geriatr Cogn Disord; 2004; 17(1-2):14-20. PubMed ID: 14560060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Treatment of Disruptive Vocalization in Dementia (Behavioral and Psychological Symptoms of Dementia) With Electroconvulsive Therapy: A Case Series.
    Lau TE; Babani PK; McMurray LA
    J ECT; 2017 Jun; 33(2):e9-e13. PubMed ID: 28009620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease.
    Workman RH; Orengo CA; Bakey AA; Molinari VA; Kunik ME
    J Neuropsychiatry Clin Neurosci; 1997; 9(4):594-7. PubMed ID: 9447503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.